Syngene International Q1 FY26 Results: Revenue from Operations up 11% to Rs. 875 Cr, EBITDA up by 19%

Syngene International Limited announced its Q1 FY26 results with a revenue from operations increase of 11% year-on-year to Rs. 875 Cr. EBITDA for the quarter increased by 19% with a reported EBITDA margin at 25%. The growth was primarily driven by continued conversion of pilot programs into longer-term contracts within the Research Services business and progress in the Biologics manufacturing division. Syngene successfully completed a USFDA Good Clinical Practices (GCP) inspection and received an Establishment Inspection Report (EIR) with a favorable Voluntary Action Indicated (VAI) outcome. The company also inaugurated a new state-of-the-art, dedicated peptide laboratory and was recognized as one of the World’s Most Sustainable Companies in 2025 by TIME magazine and Statista.